NEWS

Aldeyra Therapeutics receives orphan drug designation from FDA

Friday, Apr 21, 2017

Aldeyra Therapeutics Inc receives orphan drug designation from the U.S. Food And Drug Administration for ADX-102 in sjögren-larsson syndrome.

Aldeyra Therapeutics Inc- FDA granted Aldeyra's novel compound ADX-102 orphan drug designation for treatment of congenital ichthyosis.

Aldeyra Therapeutics Inc- pivotal phase 3 study is expected to begin later this year.

 

Source: reuters.com